Advertisement

Topics

AstraZeneca's Imfinzi Receives Breakthrough Therapy Designation

09:51 EDT 31 Jul 2017 | PharmPro

Imfinzi granted Breakthrough Therapy designation by U.S. FDA for patients with locally-advanced unresectable non-small cell lung cancer. The designation was granted on the basis of interim results from a randomized, double-blinded multi-center trial.
Contributed Author: 
Topics: 

Original Article: AstraZeneca's Imfinzi Receives Breakthrough Therapy Designation

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Imfinzi Receives Breakthrough Therapy Designation"

Quick Search
Advertisement
 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...